Kiadis grants Hospira rights to ATIR in Europe and Asia
This article was originally published in Scrip
Executive Summary
Netherlands-based Kiadis Pharma has granted Hospira of the US exclusive rights to market its novel stem cell transplant therapy, ATIR, in Europe, the Middle East, Africa, Australia and Japan, and other parts of Asia. Kiadis, which retains rights in the rest of the world, is eligible for milestone payments and royalties.